Teva To Acquire Barr

July 2008 | Company News Alert

Not to be outdone by its research-focused rivals, Israel's Teva Pharmaceutical Industries has once again demonstrated its desire to expand by acquisition, launching a US$7.46bn bid for US-based generics firm Barr Pharmaceuticals. The bid dwarfs June's flurry for industry consolidation, which included a US$4.6bn by Japan's Daiichi Sankyo for India's Ranbaxy and a (rejected) US$2.8bn bid for Czech-based Zentiva by France's Sanofi-Aventis. The Teva-Barr deal, which is expected to close by the end of 2008, will rank as the 36th largest healthcare deal in history and the third largest so far this

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.